2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 780

Urine Metabolomic Profile in Lupus Nephritis
Abstract Number: 781

Simultaneous Identification of Two Biomarkers in ACTIVE LUPUS Nephritis: Autophagy in Treg CELLS and Prolactin Receptors in B Lymphocytes
Abstract Number: 782

Cognitive Impairment and Health-Related Quality of Life in a Lupus Cohort
Abstract Number: 783

Procalcitonin and CXCL9 As Potential Biomarkers for Pneumonia in Patients with Systemic Lupus Erythematosus
Abstract Number: 784

Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE
Abstract Number: 785

Correlation between Nailfold Capillary Number and Blood Perfusion in Systemic Lupus Erythematosus Patients
Abstract Number: 786

Comparison of Nailfold Microvascular Damage in Mixed Connective Tissue Disease Versus Systemic Sclerosis Patients during a Three Year Follow-up
Abstract Number: 787

Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
Abstract Number: 788

Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis
Abstract Number: 789

The Relationship between YKL-40 and Vascular Endothelial Growth Factor in Angiogenesis in Systemic Sclerosis Patients
Abstract Number: 790

Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
Abstract Number: 791

Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Abstract Number: 792

Evaluation of Esophageal Dysmotility in Systemic Sclerosis: Clinical VALUE of Computed Tomography
Abstract Number: 793

Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis
Abstract Number: 794

Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].